TYPES OF CMT
Charcot-Marie-Tooth (CMT) disease encompasses a spectrum of inherited peripheral neuropathies that primarily affect the peripheral nerves, leading to muscle weakness and wasting, sensory loss, and various foot deformities.
There are several recognised types of Charcot-Marie-Tooth disease, each with distinct genetic causes and clinical features.
The classifications are based on clinical, genetic, and electrophysiological criteria. Each subtype of CMT can present with varying degrees of severity and progression.
Genetic testing and counselling are crucial for accurate diagnosis, prognosis, and family planning for individuals with CMT and their families.
The 6 main types of CMT
Also known as Charcot-Marie-Tooth Type 1.
Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that affect the peripheral nerves.
CMT Type 1 specifically refers to those cases where there is primarily involvement of the myelin sheath surrounding the nerves.
Here are some key features of CMT Type 1:
Genetic Basis:
It is typically inherited in an autosomal dominant manner, meaning that a mutation in one copy of the gene is sufficient to cause the disorder.
Pathophysiology:
CMT Type 1 is characterised by defects in the myelin sheath, which is the fatty substance that surrounds and insulates nerve fibres. This defect leads to slow nerve conduction velocities.
Clinical Features:
Individuals with CMT Type 1 often present with symptoms such as muscle weakness and wasting (atrophy), particularly in the lower legs and feet, resulting in difficulties with walking (gait abnormalities). They may also experience foot deformities such as high arches (pes cavus) and hammer toes.
Onset:
Symptoms typically begin in adolescence or early adulthood, although onset can vary widely even within families.
Diagnosis:
Diagnosis is usually based on clinical features, family history, and nerve conduction studies which can show reduced nerve conduction velocities.
Management:
There is currently no cure for CMT Type 1, but management focuses on supportive care and addressing symptoms. This may include physical therapy to maintain mobility and strength, orthopaedic interventions for foot deformities, and occasionally surgery.
Prognosis:
The prognosis varies, but CMT Type 1 is generally a slowly progressive disorder with a wide range of severity. Some individuals may experience relatively mild symptoms that do not significantly impact their quality of life, while others may have more severe disabilities.
It’s important for individuals with CMT Type 1 to work closely with healthcare providers, including neurologists and physical therapists, to manage symptoms and optimise their quality of life.
Also known as Charcot-Marie-Tooth Type 2, this is another subtype of Charcot-Marie-Tooth disease (CMT).
CMT is a group of inherited disorders affecting the peripheral nerves.
Unlike CMT Type 1, which primarily involves defects in the myelin sheath surrounding nerves, CMT Type 2 primarily affects the axons themselves—the long projections of nerve cells that transmit signals to other cells.
Here are some key features of CMT Type 2
Genetic Basis:
Similar to CMT Type 1, CMT Type 2 is typically inherited in an autosomal dominant manner, meaning a mutation in one copy of the gene is sufficient to cause the disorder. However, there are also autosomal recessive forms and X-linked forms of CMT Type 2.
Pathophysiology:
CMT Type 2 is characterised by abnormalities in the structure or function of the axons themselves. This leads to abnormalities in nerve conduction velocities, similar to CMT Type 1, but the primary pathology is within the axons rather than the myelin sheath.
Clinical Features:
Individuals with CMT Type 2 often present with symptoms such as muscle weakness and wasting (atrophy) that primarily affect the distal muscles of the limbs—particularly the feet and hands. This can lead to difficulties with walking, hand coordination, and fine motor skills. Foot deformities like high arches (pes cavus) and hammer toes may also occur.
Onset:
The age of onset and severity of symptoms can vary widely, even within the same family. Symptoms typically begin in adolescence or early adulthood, similar to CMT Type 1.
Diagnosis:
Diagnosis is based on clinical features, family history, and nerve conduction studies that show abnormalities in nerve conduction velocities and other nerve function tests.
Management:
There is no cure for CMT Type 2, so management focuses on supportive care and addressing symptoms. This may include physical therapy to maintain mobility and strength, orthopaedic interventions for foot deformities, and occasionally surgery.
Prognosis:
The prognosis varies depending on the specific genetic mutation and individual factors. Generally, CMT Type 2 is slowly progressive, but the rate of progression can vary. Some individuals may experience relatively mild symptoms, while others may have more severe disabilities.
As with any chronic condition, individuals with CMT Type 2 benefit from a multidisciplinary approach to care, involving neurologists, physical therapists, orthopaedists, and other specialists as needed to manage symptoms and improve quality of life.
Severe Early Onset (previously known as CMT Type 3)
Also known as Charcot-Marie-Tooth Type 3 or Dejerine-Sottas syndrome, is a severe and progressive form of Charcot-Marie-Tooth disease (CMT). It is characterised by early onset and more severe symptoms compared to other types of CMT.
Here are the key features of CMT Type 3:
Genetic Basis:
CMT Type 3 is typically inherited in an autosomal recessive manner, meaning that a person must inherit two copies of the mutated gene (one from each parent) to develop the disorder. It can also rarely be inherited in an autosomal dominant manner.
Pathophysiology:
CMT Type 3 is characterised by significant demyelination (loss of the myelin sheath) and axonal degeneration (damage to the nerve fibres). This results in severely reduced nerve conduction velocities and progressive weakness and muscle wasting (atrophy).
Clinical Features:
Individuals with CMT Type 3 usually present with symptoms in early childhood, including severe muscle weakness, especially in the legs and feet. This can lead to difficulties with walking and may require the use of assistive devices like braces or wheelchairs. They may also have sensory loss, foot deformities such as high arches (pes cavus), and decreased reflexes.
Onset:
Symptoms typically begin in infancy or early childhood and progress over time. The severity and rate of progression can vary, even within the same family.
Diagnosis:
Diagnosis is based on clinical features, family history, and nerve conduction studies that typically show significantly slowed nerve conduction velocities and other signs of peripheral nerve dysfunction.
Management:
Management focuses on supportive care to address symptoms and maintain quality of life. This may include physical therapy to improve strength and mobility, orthopaedic interventions to manage foot deformities, and other supportive measures.
Prognosis:
The prognosis for CMT Type 3 varies depending on the specific genetic mutation and individual factors. It is generally more severe and progresses more rapidly than other types of CMT. Some individuals may experience significant disability and require lifelong supportive care. Due to its severity, individuals with CMT Type 3 often require ongoing care from a multidisciplinary team of healthcare providers, including neurologists, physical therapists, orthopaedists, and genetic counsellors, to manage symptoms and provide support.
Also known as Charcot-Marie-Tooth Type 4, this is another subtype of Charcot-Marie-Tooth disease (CMT).
CMT is a group of inherited disorders affecting the peripheral nerves.
Unlike CMT Type 1 and Type 2, which primarily involve abnormalities in myelin (Type 1) or the axons (Type 2), CMT Type 4 primarily affects the Schwann cells— the cells that produce myelin and support nerve fibres.
Here are the key features of CMT Type 4
Genetic Basis:
CMT Type 4 is inherited in an autosomal recessive manner, meaning that a person must inherit two copies of the mutated gene (one from each parent) to develop the disorder. This distinguishes it from the autosomal dominant inheritance pattern seen in CMT Type 1 and Type 2.
Pathophysiology:
CMT Type 4 is characterised by defects in the Schwann cells, which results in abnormal myelination of nerve fibres. This leads to variable nerve conduction velocities, depending on the severity of the Schwann cell dysfunction.
Clinical Features:
Individuals with CMT Type 4 can present with a wide range of symptoms that typically begin in childhood or adolescence. Symptoms may include muscle weakness and wasting (atrophy) primarily affecting the distal muscles of the limbs—especially the feet and lower legs. This can lead to difficulties with walking and foot deformities such as high arches (pes cavus) and hammer toes. Sensory loss and decreased reflexes may also occur.
Onset:
The age of onset and severity of symptoms can vary widely, even within the same family. Some individuals may have milder symptoms that progress slowly over time, while others may experience more rapid progression and significant disability.
Diagnosis:
Diagnosis is based on clinical features, family history, and nerve conduction studies that typically show variable nerve conduction velocities and signs of peripheral nerve dysfunction.
Management:
There is no cure for CMT Type 4, so management focuses on supportive care and addressing symptoms. This may include physical therapy to maintain mobility and strength, orthopaedic interventions for foot deformities, and other supportive measures.
Prognosis:
The prognosis for CMT Type 4 varies depending on the specific genetic mutation and individual factors. Generally, it is slowly progressive, but the rate of progression can vary. Some individuals may experience relatively mild symptoms, while others may have more severe disabilities. As with other types of CMT, individuals with CMT Type 4 benefit from a multidisciplinary approach to care involving neurologists, physical therapists, orthopaedists, and other specialists as needed to manage symptoms and improve quality of life.
X-linked Charcot-Marie-Tooth disease (CMT) is a specific subtype of CMT that is caused by genetic mutations on the X chromosome. It is less common than the autosomal dominant and autosomal recessive forms of CMT, which are caused by mutations on non-sex chromosomes (autosomes).
Here are key features of X-linked CMT:
Genetic Basis:
X-linked CMT is caused by mutations in genes located on the X chromosome. Since males have only one X chromosome (XY), a mutation in the CMT gene on the X chromosome will result in the disease phenotype if the X chromosome inherited from the mother carries the mutation. Females (XX) have two X chromosomes, so they can be carriers if they inherit the mutated gene from one parent but typically do not show symptoms due to compensation by the normal gene on the other X chromosome.
Pathophysiology:
X-linked CMT can involve abnormalities in both myelin (Type 1) and axons (Type 2), depending on the specific gene mutation involved. This distinguishes it from other types of CMT where the inheritance pattern and the affected chromosome are different.
Clinical Features:
The clinical presentation of X-linked CMT can vary widely. Common symptoms include muscle weakness and wasting (atrophy) in the lower legs and feet, leading to difficulties with walking (gait abnormalities). Foot deformities such as high arches (pes cavus) and hammer toes may also be present. Sensory loss and decreased reflexes are also possible.
Onset:
The age of onset and severity of symptoms can vary, even within families. Symptoms may begin in childhood, adolescence, or early adulthood.
Diagnosis:
Diagnosis is based on clinical features, family history, and genetic testing to identify mutations on the X chromosome associated with CMT.
Management:
Management of X-linked CMT focuses on supportive care to address symptoms and maintain quality of life. This may include physical therapy to improve strength and mobility, orthopaedic interventions for foot deformities, and other supportive measures.
Prognosis:
The prognosis varies depending on the specific genetic mutation and individual factors. X-linked CMT is generally slowly progressive, but the rate of progression can vary. Some individuals may experience relatively mild symptoms, while others may have more severe disabilities. Because X-linked CMT follows an X-linked inheritance pattern, genetic counselling is crucial for affected families to understand the risks of passing on the condition to future generations.
Also known as intermediate Charcot-Marie-Tooth disease (CMT), refers to a subgroup within the spectrum of Charcot-Marie-Tooth disease that exhibits characteristics and features that fall between the severe Dejerine-Sottas syndrome (CMT Type 3) and the milder, more common forms like CMT Type 1 and Type 2.
Here are some key points about Intermediate CMT:
Clinical Features:
Individuals with Intermediate CMT typically exhibit symptoms that are more severe than those seen in CMT Type 1 or Type 2 but less severe than those in CMT Type 3 (Dejerine-Sottas syndrome). Symptoms commonly include muscle weakness and wasting (atrophy) affecting the distal muscles of the limbs, particularly the lower legs and feet. This can lead to difficulties with walking and foot deformities such as high arches (pes cavus).
Onset:
The age of onset and progression of Intermediate CMT can vary widely. Symptoms may start in childhood, adolescence, or early adulthood. The severity and rate of progression can also vary among affected individuals.
Genetic Basis:
Intermediate CMT can have different genetic causes. It may result from mutations in genes that affect both the myelin sheath and the nerve fibres (axons). The inheritance pattern can be autosomal dominant, autosomal recessive, or X-linked, depending on the specific genetic mutation.
Diagnosis:
Diagnosis is typically based on clinical features, family history, and nerve conduction studies. Nerve conduction studies in Intermediate CMT often show nerve conduction velocities that are intermediate between those seen in typical CMT Type 1 and the severely slowed velocities seen in CMT Type 3.
Management:
Management of Intermediate CMT focuses on supportive care to address symptoms and improve quality of life. This may include physical therapy to maintain strength and mobility, orthopaedic interventions for foot deformities, and assistive devices as needed.
Prognosis:
The prognosis for Intermediate CMT varies depending on the specific genetic mutation and individual factors. It is generally more severe than typical CMT Type 1 or Type 2 but less severe than CMT Type 3. The rate of progression can vary, and some individuals may experience significant disability while others may have milder symptoms. Because Intermediate CMT encompasses a range of severity and genetic causes, it is important for affected individuals to receive comprehensive care from a multidisciplinary team including neurologists, genetic counsellors, physical therapists, and other specialists as needed. Genetic testing and counselling are also essential for affected families to understand the inheritance pattern and risks.
